DAIICHI SANKYOUS Corporate Headquarters

Parsippany, NJ

November 3, 2006

Rutgers Business SchoolSite Visit Prep SessionRyan FieldIffat Ali

Daiichi Sankyo Co., Ltd.

Daiichi Pharmaceutical Co. founded 1915

Sankyo established 1899

Merged September 2005Second largest Japanese pharma company

$7.9B (North America: 12.5%)*

Focus on pharmaceutical products

Takashi Shoda, President, CEO, and Representative Director of Board of Directors

*Note: Financial information is from FY ending March 2006

Daiichi Sankyo’s Legacy

Washington DC cherry trees donated in 1912 by first president of Sankyo, Jokichi Takamine

Daiichi Sankyo, Inc.

US integrated operations:Established April 2006

Headquarters:2 Hilton Court

Parsippany, NJ 07054

(973) 359-2600

Website:www.daiichisankyo-us.com

Integration of US Subsidiaries

Three subsidiaries:Sankyo Pharma Inc.

Daiichi Pharmaceutical Corp.

Daiichi Medical Research

Joe Pieroni, president of Daiichi Sankyo, US

Integration of US Subsidiaries

Combined sales force

Primary focus on cardiovascular disease

Additional R&D areas:Glucose metabolic disorders

Infectious diseases

Cancer

Immunology

Bone and joint diseases

Daiichi SankyoPharma Development

Product developmentClinical development

Translational medicine

Clinical pharmacology

Regulatory affairs

Risk management

Informatics and knowledge management

Biostatistics and data operations

Development research

Daiichi SankyoResearch Institute (DSRI)

Building relationshipsAcademic institutions

Biotechnology firms

Research alliances

Manage partnership with venture funds

Alliances with Biotechnology Firms

KAI Pharmaceuticals

MorphoSys

Exelixis

US Products

WelCholCholesterol lowering

15-18% reduction in LDL

Non-systemicNot absorbed into bloodstream

Binds to bile acids in the intestines,

carries out of body

Can be used in combination with

a statin drug

US Products

BenicarHypertension (high blood pressure)

Angiotensin receptor blocker (ARB)

Benicar HCTBenicar + thiazide diuretic (HCTZ)

HCTZ works by increasing water excretion

Complimentary effect on reducing HBP

Not intended for initial treatment

US Products

Floxin OticEardrop antibiotic

Children / Adults

Otitis Media / Otitis Externa Middle / Outer ear infection (swimmer’s ear)

Two packagesBottles

Single use vials

US Products

EvoxacSjögren's syndrome

Dry mouth symptoms

Stimulates natural flow of saliva

Product Pipeline

Development code number

Class or application Developmental stage (1Q2006)

CS-747 (prasugrel) Oral antiplatelet agent Phase III

Colesevelam Diabetes (BAS) Phase III

CS-8663 Hypertension Phase III

CS-011 (rivoglitazone) Diabetes (PPAR) Phase II-III

KAI (9803) Ischemia-reperfusion injury (PKC Inhibitor)

Phase II

DJ-927 Cancer chemotherapeutic (Taxane) Phase II

DU-176b Anticoagulant.(Factor Xa Inhibitor) Phase II

CS-917 Diabetes (FBPase Inhibitor) Phase II

CS-3030 Anticoagulant.(Factor Xa Inhibitor) Phase I

DA-697b Novel anti-platelet Phase I

CS-7017 Oncology (PPAR gamma) Phase I

CS-1008 Oncology (DR5) Phase I

CS-0777 Immunosuppressive Pre-clinical

Topics for TomorrowProgram begins at 1:00PM

Overview of Daiichi Sankyo and the Management Development Program

New Product Planning

Supply Chain and Sales Operations

Product Management/Market Research

Facility Tour

Managed Care